• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Neurology

Donanemab improved cognitive measures in early Alzheimer’s disease

byAvneesh BhanguandHarsh Shah
March 17, 2021
in Neurology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Donanemab resulted in a modestly better composite score for cognition and the ability to perform activities of daily living in patients with early Alzheimer’s disease compared to placebo.

2. Treatment with donanemab resulted in amyloid-related imaging abnormalities.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Buildup of amyloid-β (Aβ) peptide in amyloid plaques is found in early Alzheimer’s disease and leads to functional and cognitive impairment. Donanemab is an IgG1 antibody directed at an Aβ epitope present in established plaques. This trial evaluated the safety and efficacy of donanemab in patients with early Alzheimer’s disease. This trial found that donanemab resulted in a better composite score for cognition and performance in activities of daily living compared to placebo after 76 weeks in patients with early Alzheimer’s disease. However, the results for most secondary outcomes between the donanemab and placebo groups showed no substantial difference, including the Clinical Dementia Rating Scale-Sum of Boxes. Limitations included small sample size and the potential of survivor bias as there was a higher incidence of trial discontinuation in the donanemab group compared to the placebo group. Nonetheless, this study’s results are significant and showed donanemab can lead to a modestly less cognitive and functional decline compared to placebo.

Click to read the study in NEJM

Relevant Reading: Significant and sustained florbetapir f18 uptake reduction in patients with symptomatic Alzheimer’s disease with ly3002813, a β‐amyloid plaque‐specific antibody.

In-Depth [randomized controlled trial]: This double-blind randomized controlled trial enrolled 257 patients across 56 sites in the United States and Canada. The patients were randomized in a 1:1 ratio into either the donanemab group or the placebo group, respectively. Patients 60 to 85 years of age who had early symptomatic Alzheimer’s disease and had a Mini-Mental State Examination (MMSE) score of 20-28 were included in the study. Patients with a tau standardized uptake value ratio of more than 1.46 were excluded from the study. The primary outcome was a change in the Integrated Alzheimer’s Disease Rating Scale (iADRS) score from baseline to 76 weeks. A lower score indicated a greater cognitive deficit and greater impairment to perform activities of daily living. From baseline, the change in the iADRS score at 76 weeks was -6.86 in the donanemab group and -10.06 in the placebo group (difference, 3.20; 95% confidence interval [CI], 0.12 to 6.27; P=0.04). The change between both groups in the Clinical Dementia Rating Scale-Sum of Boxes score was -0.36 (95% CI, -0.83 to 0.12) and 0.64 (95% CI, -0.40 to 1.67) for the MMSE score. No significant difference in the incidence of death or serious adverse events between the two groups was found; however, the incidence of amyloid-related imaging abnormalities with edema or effusions was significantly higher in the donanemab group (26.7%) compared to placebo (0.8%). Altogether, this trial shows that in patients with early symptomatic Alzheimer’s disease, donanemab treatment resulted in less cognitive and functional decline, but resulted in amyloid-related imaging abnormalities.

RELATED REPORTS

#VisualAbstract: Anti-tau antibody Semorinemab not shown to slow clinical progression of Alzheimer’s disease

Anti-tau antibody Semorinemab not shown to slow clinical progression of Alzheimer’s disease

Rare APOE missense variants V236E and R251G associated with substantial reduction in risk of Alzheimer disease

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Alzheimer’s diseasecognitive outcomesDonanemab
Previous Post

Telephone cognitive behavioral therapy for insomnia in adults With osteoarthritis pain

Next Post

#VisualAbstract: Salpingo-oophorectomy may reduce short-term risk of breast cancer in women with BRCA1 and BRCA2 variants

RelatedReports

#VisualAbstract: Varenicline improves successful smoking cessation amongst African American daily smokers: KIS-IV Trial
StudyGraphics

#VisualAbstract: Anti-tau antibody Semorinemab not shown to slow clinical progression of Alzheimer’s disease

June 29, 2022
Genetic risk assessment for Alzheimer’s disease does not increase anxiety, depression or stress
Chronic Disease

Anti-tau antibody Semorinemab not shown to slow clinical progression of Alzheimer’s disease

June 17, 2022
Amyloid pathology may be detected decades prior to Alzheimer’s diagnosis
Chronic Disease

Rare APOE missense variants V236E and R251G associated with substantial reduction in risk of Alzheimer disease

June 2, 2022
Genetic risk assessment for Alzheimer’s disease does not increase anxiety, depression or stress
Chronic Disease

Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms

May 26, 2022
Next Post
#VisualAbstract: Salpingo-oophorectomy may reduce short-term risk of breast cancer in women with BRCA1 and BRCA2 variants

#VisualAbstract: Salpingo-oophorectomy may reduce short-term risk of breast cancer in women with BRCA1 and BRCA2 variants

Study explores effects of daily iron supplementation in 2- to 5-year-olds

Pegcetacoplan improved hemoglobin levels in eculizumab-treated paroxysmal nocturnal hemoglobinuria patients

Intensive rehabilitation not superior to traditional therapy for arm function after stroke

Non-consensus transient ischemic attacks linked to high short-term and long-term risks of stroke  

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Stereotactic body radiotherapy as a state of the art treatment option in inoperable non-small cell lung cancer [Classics Series]
  • Health system-based care associated with better treatment use and high rates of tobacco abstinence at 3 months post-discharge in hospitalized smokers
  • APOEε4 genotype may increase risk of chronic traumatic encephalopathy following repetitive head impact
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.